Effects of perturbations of pools of deoxyribonucleoside triphosphates on expression of ribonucleotide reductase, a G1/S transition state enzyme, in p53-mutated cells

Biochemical Pharmacology

Volumn 55, Issue 9, 1998, Pages 1353-1360

  Wadler, Scott ^a   Horowitz, Robert ^a   Zhang, Hong Yang ^a   Schwartz, Edward L ^a  

^a ALBERT EINSTEIN CANCER CENTER   (United States)

Author keywords

5 fluorouracil; Cytokinesis; Deoxyribonucleoside triphosphates; Hydroxyurea; p53; Ribonucleotide reductase

Indexed keywords

ANTIMETABOLITE; BROXURIDINE; DEOXYRIBONUCLEOSIDE TRIPHOSPHATE; DNA; FLUOROURACIL; HYDROXYUREA; MESSENGER RNA; PROTEIN P53; RECOMBINANT ALPHA2A INTERFERON; RIBONUCLEOTIDE REDUCTASE;

ARTICLE; CANCER CHEMOTHERAPY; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL DEATH; CELL PROLIFERATION; COLON CANCER; CONTROLLED STUDY; CYTOKINESIS; DRUG EFFECT; FLOW CYTOMETRY; GENE MUTATION; HUMAN; HUMAN CELL; NORTHERN BLOTTING; PRIORITY JOURNAL; PURINE SYNTHESIS; PYRIMIDINE SYNTHESIS;

CELL CYCLE; CELL DIVISION; COLONIC NEOPLASMS; DEOXYRIBONUCLEOTIDES; FLUOROURACIL; G1 PHASE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; HUMANS; HYDROXYUREA; INTERFERON ALFA-2A; MACROMOLECULAR SUBSTANCES; MUTATION; RIBONUCLEOTIDE REDUCTASES; RNA, MESSENGER; S PHASE; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED;

EID: 0032499432     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(97)00641-2     Document Type: Article

References (41)

1. Wang J, Walsh K. Resistance to apoptosis conferred by Cdk inhibitors during myocyte differentiation. Science. 273:1996;359-361.
2. Almasan A, Yin Y, Kelly RE, Lee EY-HP, Bradley A, Li W, Bertino JR, Wahl GM. Deficiency of retinoblastoma protein leads to inappropriate S-phase entry, activation of E2F-responsive genes, and apoptosis. Proc Natl Acad Sci USA. 92:1995;5436-5440.
3. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 51:1991;6304-6311.
4. Nutt CL, Chambers AF, Cairncross JG. Wild-type p53 renders mouse astrocytes resistant to 1,3-bis(2-chloroethyl)-1-nitrosourea despite the absence of a p53-dependent cell cycle arrest. Cancer Res. 56:1996;2748-2751.
5. Kuerbitz SJ, Plunkett BS, Walsh WV, Kastan MB. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA. 89:1992;7491-7495.
6. Bracey TS, Miller JC, Preece A, Paraskeva C. γ-Radiation-induced apoptosis in human colorectal adenoma and carcinoma cell lines can occur in the absence of wild type p53. Oncogene. 10:1995;2391-2396.
7. 1 cell cycle arrest induced by ribonucleotide depletion in the absence of detectable DNA damage. Genes Dev. 10:1996;934-947.
8. Lawrence TS, Davis MA, Loney TL. Fluoropyrimidine-mediated radiosensitization depends on cyclin E-dependent kinase activation. Cancer Res. 56:1996;3203-3206.
9. Wadler S, Horowitz R, Mao X, Schwartz EL. Effect of interferon on 5-fluorouracil-induced perturbations in pools of deoxynucleotide triphosphates and DNA strand breaks. Cancer Chemother Pharmacol. 38:1996;529-535.
10. Goyette MC, Cho K, Fasching CL, Levy DB, Kinzler KW, Paraskeva CP, Vogelstein B, Stanbridge EJ. Progression of colorectal cancer is associated with multiple tumor suppressor gene defects but inhibition of tumorigenicity is accomplished by correction of any single defect via chromosome transfer. Mol Cell Biol. 12:1992;1387-1395.
11. Kastan MB, Zhan Q, El-Deiry WS, Carrier F, Jacks T, Walsh WV, Plunkett BS, Vogelstein B, Fornace AJ Jr. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell. 71:1992;587-597.
12. Harris CC. p53 At the crossroads of molecular carcinogenesis and risk assessment . Science. 262:1992;1980-1981.
13. Hollestein M, Sidransky D, Vogelstein B, Harris CC. p53 Mutations in human cancers. Science. 253:1991;49-53.
14. Hupp TR, Meek DW, Midgley CA, Lane DP. Activation of the cryptic DNA binding function of mutant forms of p53. Nucleic Acids Res. 21:1993;3167-3174.
15. Halazonetis TD, Kandil AN. Conformational shifts propagate from the oligomerization domain of p53 to its tetrameric DNA binding domain and restore DNA binding to select p53 mutants. EMBO J. 12:1993;5057-5064.
16. Bjorklund S, Skog S, Tribukait B, Thelander L. S-Phase-specific expression of mammalian ribonucleotide reductase R1 and R2 subunit mRNAs. Biochemistry. 29:1990;5452-5458.
17. Albert DA, Rozengurt E. Synergistic and coordinate expression of the genes encoding ribonucleotide reductase subunits in Swiss 3T3 cells Effect of multiple signal-transduction pathways . Proc Natl Acad Sci USA. 89:1992;1597-1601.
18. Wadler S, Wersto R, Weinberg V, Thompson D, Schwartz EL. Interaction of fluorouracil and interferon in human colon cancer cell lines Cytotoxic and cytokinetic effects . Cancer Res. 50:1990;5735-5739.
19. Wadler S, Horowitz R, Rao J, Mao X, Schlesinger K, Schwartz EL. Interferon augments the cytotoxicity of hydroxyurea without enhancing its activity against the M2 subunit of ribonucleotide reductase Effects in wild-type and resistant human colon cancer cells . Cancer Chemother Pharmacol. 38:1996;522-528.
20. Sherman PA, Fyfe JA. Enzymatic assay for deoxyribonucleotide triphosphates using synthetic oligonucleotides as template primers. Anal Biochem. 180:1989;222-226.
21. Wadler S, Mao X, Bajaj R, Schwartz EL. Interaction between 5-fluorouracil/interferon-α-2a and N-(phosphonacetyl)-L-aspartate (PALA) in human colon cancer cell lines is mediated through RNA effects. Mol Pharmacol. 44:1993;1070-1076.
22. Van Laar T, Schouten R, Jochemsen AG, Terleth C, van der Eb AJ. Temperature-sensitive mutant p53 (ala143) interferes transiently with DNA-synthesis and cell-cycle progression in Saos-2 cells. Cytometry. 25:1996;21-31.
23. Engstrom Y, Francke U. Assignment of the structural gene for subunit M1 and human ribonucleotide reductase to the short arm of chromosome 11. Exp Cell Res. 158:1985;477-483.
24. Thelander M, Graslund A, Thelander L. Subunit M2 of mammalian ribonucleotide reductase. Characterization of a homogeneous protein isolated from M2-overproducing mouse cells. J Biol Chem. 260:1985;2737-2741.
25. Thelander L, Berg P. Isolation and characterization of expressible cDNA clones encoding the M1 and M2 subunits of mouse ribonucleotide reductase. Mol Cell Biol. 6:1986;3433-3442.
26. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst. 82:1990;1107-1112.
27. Johnson CE, Hughes K, Cory JG. Cell-cycle associated transcriptional regulation of ribonucleotide reductase in L1210 leukemia cells and drug-resistant variants. Cancer Commun. 3:1991;341-349.
28. Mann GJ, Musgrove EA, Fox RM, Thelander L. Ribonucleotide reductase M1 subunit in cellular proliferation, quiescence and differentiation. Cancer Res. 48:1988;5151-5156.
29. Chou T-C, Talalay P. Quantitative analysis of dose-effect relationships The combined effects of multiple drugs or enzyme inhibitors . Adv Enzyme Regul. 22:1984;27-55.
30. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-Dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell. 74:1993;957-967.
31. Kinzler KW, Vogelstein B. Clinical implications of basic research Cancer therapy meets p53 . N Engl J Med. 331:1994;49-50.
32. Chin KV, Ueda K, Pastan I, Gottesman M. Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science. 255:1992;459-462.
33. Matsui S-i, Arredondo MA, Wrzosek C, Rustum YM. DNA damage and p53 induction do not cause ZD1694-induced cell cycle arrest in human colon carcinoma cells. Cancer Res. 56:1996;4715-4723.
34. Wataya Y, Watanabe K, Yoshida S, Hiramoto-Yoshioka A. dNTP imbalance and DNA double strand breaks in mouse FM3A cells and the mechanism of cell death. Nucleic Acids Symp Ser. 21:1989;11-12.
35. Hwang H, Ohtani M, Nakazawa T, Igaki T, Masui O, Kankawa S, Nakayama C, Yoshida S, Yoshioka-Hiramoto A, Wataya Y. Molecular mechanism of 5-fluoro-2′-deoxyuridine-induced dNTP imbalance cell death Purification of an endonuclease involved in DNA double strand breaks during dNTP imbalance death . Nucleosides Nucleotides. 14:1995;2089-2097.
36. Yoshioka A, Tanaka S, Hiraoka O, Koyama Y, Hirota Y, Ayusawa D, Seno T, Garrett C, Wataya Y. Deoxyribonucleostide triphosphate imbalance 5-Fluorodeoxyuridine-induced DNA double strand breaks in mouse FM3A cells and the mechanism of cell death . J Biol Chem. 262:1987;8235-8241.
37. Reddy GP, Fager RS. Replitase A complex integrating dNTP synthesis and DNA replication . Crit Rev Eukaryot Gene Expr. 3:1993;255-277.
38. Amara FM, Hurta RAR, Huang A, Wright JA. Altered regulation of message stability and tumor promoter-responsive cis-trans interactions of ribonucleotide reductase R1 and R2 messenger RNAs in hydroxyurea-resistant cells. Cancer Res. 55:1995;4503-4506.
39. Amara FM, Chen FY, Wright JA. Phorbol ester modulation of a novel cytoplasmic protein binding activity at the 3′ untranslated region of mammalian ribonucleotide reductase R2 mRNA and role in message stability. J Biol Chem. 269:1994;6709-6715.
40. Chen FY, Amara FM, Wright JA. Mammalian ribonucleotide reductase R1 mRNA stability under normal and phorbol ester stimulating conditions Involvement of a cis-trans interaction at the 3′ untranslated region . EMBO J. 12:1993;3977-3986.
41. Wright JA, Chan AK, Choy BK, Hurta RA, McClarty GA, Tagger AY. Regulation and drug resistance mechanisms of mammalian ribonucleotide reductase and the significance to DNA synthesis. Biochem Cell Biol. 68:1990;1364-1371.